Allergy Therapeutics Share Discussion Threads

[beccasan] 03/6/2024 07:02

These RNS, clearly written to write something and based on nothing supported by nothing, remind me of when they promised to have the cure for cancer. Which if it wasn't immoral would be ridiculous.

[jimmyloser] 03/6/2024 06:07

What a start to the week.......................


Monday, Monday, so good to me
Monday mornin', it was all I hoped it would be

*Mama's and Papa's

Brilliant work from the team @ Allergy Therapeutics - Just brilliant!

[beccasan] 31/5/2024 07:17

Number of posters 12, number of studies published 0....😂

[jimmyloser] 31/5/2024 06:04

RNS Number : 5401Q
Allergy Therapeutics PLC
31 May 2024




Porto
Allergy Therapeutics plc

("Allergy Therapeutics" or "the Group")





Allergy Therapeutics presents scientific findings from research portfolio at EAACI 2024



31 May 2024 Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy vaccines, today announces that it will be sharing key scientific findings from across its research portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place from today until 3 June 2024 in Valencia, Spain.



The EAACI Congress is the world's largest scientific conference that specialises in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology, an association of more than 16,000 clinicians, researchers and allied health professionals from 124 countries, dedicated to improving the health of people affected by allergic diseases.



Among its 12 posters being presented, Allergy Therapeutics will share:

· The positive results from the pivotal Phase III G306 trial, which evaluated the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. The trial successfully met its primary endpoint, as previously announced on 14 November 2023. The findings from the G306 trial, alongside results of the earlier G309 exploratory field study, will support the Group's marketing authorisation application (MAA), with a planned submission in Q4 2024.

· Results from analysis of patient and caregiver preferences for different venom and pollen immunotherapy approaches and their implications on adherence and treatment acceptance.

· The beneficial safety and tolerability results from the healthy subject subcutaneous dosing cohorts of the Phase I/IIa PROTECT trial of the Group's novel virus-like-particle (VLP)-based peanut allergy vaccine candidate ("VLP Peanut"), without any major safety or tolerability findings. This ongoing trial progressed in March 2024 to subcutaneous dosing of peanut allergic patients, marking the start of the clinical proof of concept phase using biomarkers to assess preliminary efficacy.



Allergy Therapeutics will also be hosting a symposium, "Setting a new standard for grass subcutaneous immunotherapy," on Sunday, 2 June, 13:45-14:45 CEST, chaired by Professor Dr. Stefan Zielen, Head of the Institute for Respiratory Medicine, Frankfurt, Germany. The symposium will include presentations covering regulatory and clinical challenges in allergen immunotherapy trials, as well as results from the Group's pivotal Phase III G306 trial of Grass MATA MPL by key experts from the US and EU.



In addition, Prof. Mohamed Shamji from Imperial College, London and EAACI Vice President Congresses, will showcase the Group's scientific adaptive approaches to clinical development, as applied in the successful G309 and G306 studies, as examples of current state-of-the-art clinical development in a plenary session.



Finally, Prof. Shamji will host an embargo session at the closure day of the EAACI conference to release the Group's recently accepted VLP Peanut paper in the peer reviewed Journal of Allergy and Clinical Immunology, the official publication of the American Academy of Allergy, Asthma, and Immunology (AAAAI). This session will highlight the promising biomarker safety and efficacy profile of VLP Peanut, including the first clinical results supporting the hypo-allergic profile of VLP Peanut based on the skin test results from the PROTECT Phase I/IIa study.



Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: "At Allergy Therapeutics, our mission is to transform lives by breaking new ground in immunology treatments, and we are thrilled to have such a robust presence at this year's EAACI Congress. The research we are sharing demonstrates the strength of our science and, with one innovative short-course allergy immunotherapy targeting peanut allergy currently in the clinic and another targeting grass pollen allergy progressing towards a planned market authorisation application, we are steadfast in our commitment to helping patients change the way they think about their allergies and better manage their conditions."

[jimmyloser] 29/5/2024 05:51

Farmer G.
Based on..............

Significant clinical and regulatory progress

Financial turnaround on track. Strengthened balance sheet and restructuring plan paves the way to future growth.



- Primary end point met in G306 Pivotal Study for Grass Allergic Patients

- Successful development of VLP Peanut vaccine program underpins the phase I/IIa study.

[totally banjo] 28/5/2024 23:45

I think "expectation" is why we have seen the rise over last few months! If I remember right the USA peanut trials end about this time next year but I could be wrong?

I'll do some more research from now on as it may or may not get quite exciting over next year or so.

After losing all my investment money via VOG I don't have much interest in this share game anymore :-(

[farmergeorge] 28/5/2024 21:23

jimmy, based on what?

[jimmyloser] 28/5/2024 21:01

Expectation!

[farmergeorge] 28/5/2024 19:39

No recent news.

[totally banjo] 28/5/2024 19:05

are we due any news/update to account for positive rise over last few months? Think I bought in at 20p+ many years ago and just held onto them............as you do :-)

[farmergeorge] 28/5/2024 19:04

So, why is it sought - hope value?

[jimmyloser] 28/5/2024 18:43

See 4896 FarmerG"One of the most sort after shares on AIM"Providing they don't do an Allergy that is

[farmergeorge] 28/5/2024 18:30

Same here jimmy. What's going on behind the scenes, if anything?

[red army] 28/5/2024 18:29

This peanut allergy is a massive market.

[jimmyloser] 28/5/2024 18:13

Let me be the first to admit this price rise has left me happily shocked.
I was hoping for 5p by Christmas but now I am of the mind that Christmas will be coming early this year!

Time to take the 'smooth' with the rough which makes for a pleasant change here.

[farmergeorge] 24/5/2024 07:42

jimmyloser, all noted thanks.

[jimmyloser] 24/5/2024 06:40

The news is out there (impo) FarmerG.
The market hasn’t yet grasped the breakthroughs that AGY have been making over the last year or so.
I posted around Christmas that I could see this becoming one of the most sort after shares on AIM and I stick to that.
Providing they don’t have another setback, then we may well witness a buying frenzy later this year, (when they apply for marketing approval) the likes of which we have never seen on here, as ‘speculators’ join us long term investors.
IMPO
DYOR
Fingers crossed

[farmergeorge] 23/5/2024 15:44

Went up by 0.50p at one point. Any news?

[jimmyloser] 23/5/2024 15:26

Quiet please, listen, the Penny is dropping!

[jpuff] 15/5/2024 16:52

Maybe signs of a bit of momentum gathering here now. I'm holding tight and adding a few as and when the missus hasn't raided the wallet.

[jimmyloser] 15/5/2024 16:07

Tantalising indeed.

[jimmyloser] 07/5/2024 09:42

I like your choice of tantalising!

[jpuff] 07/5/2024 09:28

Starting to look tantalising Jimmy

[jimmyloser] 07/5/2024 06:22

And don't forget that we are NOT a one trick pony!Peanut is hot on the heelsPatience.

[jimmyloser] 07/5/2024 06:04

My case rests M’lud.